NCOA4 and neoplasm: Tumor protein, collected at the end of treatment on day 14 for NCOA4-RET and ΔRET, revealed significant reduction in the fusion protein levels and downstream PI3K-AKT signaling for the cabozantinib-treated groups as measured by western blot (Fig. 5c and Supplementary Fig. 4d).